Treatment intensification of external beam radiotherapy (EBRT) plays a crucial role in the treatment of high-risk prostate cancer.
We performed a critical narrative review of the relevant literature and present new developments in evidence-based treatment intensification strategies.
For men with high-risk prostate cancer, there is strong evidence to support prolonging androgen deprivation therapy (ADT) to 18-36 months and escalating the dose to the prostate using a brachytherapy boost. A potentially less toxic alternative to a brachytherapy boost is delivering a focal boost to dominant intraprostatic lesions using EBRT. In patients who meet STAMPEDE high-risk criteria, there is evidence to support adding a second-generation anti-androgen agent, such as abiraterone acetate, to long-term ADT. Elective pelvic lymph node irradiation may be beneficial in select patients, though more prospective data is needed to elucidate the group of patients who may benefit the most. Tumor genomic classifier (GC) testing and advanced molecular imaging will likely play a role in improving patient selection for treatment intensification as well as contribute to the evolution of treatment intensification strategies for future patients.
Treatment intensification using a combination of EBRT, advanced hormonal therapies, and brachytherapy may improve patient outcomes and survival in men with high-risk prostate cancer. Shared decision-making between patients and multidisciplinary teams of radiation oncologists, urologists, and medical oncologists is essential for personalizing care in this setting and deciding which strategies make sense for individual patients.
World journal of urology. 2024 Mar 16*** epublish ***
John Nikitas, Amar Kishan, Albert Chang, Sai Duriseti, Nicholas G Nichols, Robert Reiter, Matthew Rettig, Wayne Brisbane, Michael L Steinberg, Luca Valle
Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, USA., Department of Urology, University of California, Los Angeles, Los Angeles, USA., Radiation Oncology Service, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, USA. .